Investors sentiment increased to 1.57 in Q2 2019. Its up 0.29, from 1.28 in 2019Q1. It improved, as 24 investors sold Sangamo Therapeutics, Inc. shares while 32 reduced holdings. 26 funds opened positions while 62 raised stakes. 73.13 million shares or 14.12% more from 64.08 million shares in 2019Q1 were reported.
Parallax Volatility Advisers Lp reported 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Sector Gamma As holds 0.44% or 251,698 shares. 111,700 were accumulated by California Public Employees Retirement Sys. Rhenman & Asset Management owns 793,957 shares or 0.94% of their US portfolio. Renaissance Technologies Lc reported 626,800 shares. Virginia Retirement Systems Et Al reported 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Minnesota-based Us Bancshares De has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). 68,869 are held by Edge Wealth Ltd Llc. Bailard accumulated 175,600 shares. Charles Schwab Mngmt Inc holds 676,556 shares. 59 are owned by Next Financial. Moreover, State Board Of Administration Of Florida Retirement Sys has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 58,315 shares. Parametric Limited Liability Co accumulated 91,682 shares. Moreover, Amalgamated Commercial Bank has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 19,506 shares. Janney Montgomery Scott Lc reported 10,378 shares.
The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a huge mover today! The stock increased 6.97% or $0.75 during the last trading session, reaching $11.44. About 2.00 million shares traded or 75.52% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has declined 8.32% since December 3, 2018 and is downtrending. It has underperformed by 8.32% the S&P500.
The move comes after 8 months positive chart setup for the $1.33B company. It was reported on Dec, 3 by Barchart.com. We have $12.36 PT which if reached, will make NASDAQ:SGMO worth $106.08 million more.
Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.30 earnings per share, down 66.67 % or $0.12 from last year’s $-0.18 per share. After $-0.24 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 25.00 % negative EPS growth.
More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Nasdaq.com which released: “BUZZ-U.S. STOCKS ON THE MOVE-Retail stocks, CRISPR Therapeutics, Slack Technologies – Nasdaq” on November 19, 2019, also Businesswire.com with their article: “Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation – Business Wire” published on November 19, 2019, Nasdaq.com published: “First Week of January 2020 Options Trading For Sanofi (SNY) – Nasdaq” on November 26, 2019. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Nasdaq.com and their article: “Noteworthy ETF Outflows: XLY – Nasdaq” published on November 26, 2019 as well as Seekingalpha.com‘s news article titled: “Gene therapy stocks in focus after Astellas/Audentes deal – Seeking Alpha” with publication date: December 03, 2019.
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.33 billion. The company??s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.